IL304365B2 - A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof - Google Patents
A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereofInfo
- Publication number
- IL304365B2 IL304365B2 IL304365A IL30436523A IL304365B2 IL 304365 B2 IL304365 B2 IL 304365B2 IL 304365 A IL304365 A IL 304365A IL 30436523 A IL30436523 A IL 30436523A IL 304365 B2 IL304365 B2 IL 304365B2
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- analog
- amino acid
- amino acids
- long
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210042305 | 2021-03-31 | ||
| PCT/KR2022/004620 WO2022211537A1 (ko) | 2021-03-31 | 2022-03-31 | 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL304365A IL304365A (en) | 2023-09-01 |
| IL304365B1 IL304365B1 (en) | 2024-12-01 |
| IL304365B2 true IL304365B2 (en) | 2025-04-01 |
Family
ID=83459706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304365A IL304365B2 (en) | 2021-03-31 | 2022-03-30 | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12599675B2 (enExample) |
| EP (1) | EP4316528A4 (enExample) |
| JP (1) | JP2024512418A (enExample) |
| KR (2) | KR102680146B1 (enExample) |
| CN (1) | CN116916969A (enExample) |
| AR (1) | AR125263A1 (enExample) |
| AU (1) | AU2022209248B2 (enExample) |
| BR (1) | BR112023018530A2 (enExample) |
| CA (1) | CA3205058C (enExample) |
| CL (1) | CL2023002504A1 (enExample) |
| IL (1) | IL304365B2 (enExample) |
| MX (1) | MX2023010926A (enExample) |
| PE (1) | PE20250672A1 (enExample) |
| WO (1) | WO2022211537A1 (enExample) |
| ZA (1) | ZA202307219B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4185605A4 (en) * | 2020-07-09 | 2024-07-17 | Eutilex Co., Ltd. | IL-2 VARIANTS |
| WO2024136575A1 (ko) | 2022-12-23 | 2024-06-27 | 한미약품 주식회사 | 면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제 |
| TW202502372A (zh) * | 2023-03-07 | 2025-01-16 | 南韓商韓美藥品股份有限公司 | 包含ｉｌ－２類似物或其接合物之用於預防或治療癌症之醫藥組成物 |
| IL322698A (en) * | 2023-03-07 | 2025-10-01 | Hanmi Pharmaceutical Co Ltd | Combination therapy containing interleukin 2 analogs or conjugates and immune checkpoint inhibitors for the prevention or treatment of cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089420A1 (en) * | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
| KR20200078312A (ko) * | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| KR100507796B1 (ko) * | 2003-04-03 | 2005-08-17 | 한미약품 주식회사 | 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법 |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EP3834838A1 (en) * | 2014-02-21 | 2021-06-16 | Nektar Therapeutics (India) Pvt. Ltd. | Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody |
| WO2016014428A2 (en) * | 2014-07-21 | 2016-01-28 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP3943101A1 (en) | 2014-10-21 | 2022-01-26 | SciClone Pharmaceuticals International Ltd. | Treatment of cancer with immune stimulator alpha thymosin peptide |
| EP3341025A4 (en) * | 2015-09-24 | 2019-05-01 | Hanmi Pharm. Co., Ltd. | PROTEIN COMPLEX BY USING A SPECIFIC ROLE OF AN IMMUNOMOBILIN FRAGMENT FOR LINKING |
| CN115073581A (zh) * | 2016-05-04 | 2022-09-20 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
| KR102050463B1 (ko) * | 2016-08-10 | 2019-11-29 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 |
| PH12020550661A1 (en) * | 2017-11-21 | 2021-04-19 | Univ Leland Stanford Junior | Partial agonists of interleukin-2 |
| CN119504973A (zh) * | 2018-03-28 | 2025-02-25 | 阿森迪斯药物肿瘤股份有限公司 | Il-2缀合物 |
| JP7550745B2 (ja) | 2018-07-24 | 2024-09-13 | バイオエヌテック エスエー | Ｉｌ２アゴニスト |
| US12269855B2 (en) * | 2018-09-21 | 2025-04-08 | Innovent Biologics (Suzhou) Co., Ltd. | Interleukin-2 and use thereof |
| TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | Ｉｌ２激動劑 |
| CA3147677A1 (en) * | 2019-08-13 | 2021-02-18 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta agonists |
-
2022
- 2022-03-30 IL IL304365A patent/IL304365B2/en unknown
- 2022-03-31 US US18/000,096 patent/US12599675B2/en active Active
- 2022-03-31 AU AU2022209248A patent/AU2022209248B2/en active Active
- 2022-03-31 BR BR112023018530A patent/BR112023018530A2/pt unknown
- 2022-03-31 MX MX2023010926A patent/MX2023010926A/es unknown
- 2022-03-31 PE PE2023002484A patent/PE20250672A1/es unknown
- 2022-03-31 EP EP22781656.8A patent/EP4316528A4/en active Pending
- 2022-03-31 CN CN202280017977.7A patent/CN116916969A/zh active Pending
- 2022-03-31 AR ARP220100795A patent/AR125263A1/es unknown
- 2022-03-31 CA CA3205058A patent/CA3205058C/en active Active
- 2022-03-31 JP JP2023555563A patent/JP2024512418A/ja active Pending
- 2022-03-31 WO PCT/KR2022/004620 patent/WO2022211537A1/ko not_active Ceased
- 2022-03-31 KR KR1020220040626A patent/KR102680146B1/ko active Active
-
2023
- 2023-07-19 ZA ZA2023/07219A patent/ZA202307219B/en unknown
- 2023-08-24 CL CL2023002504A patent/CL2023002504A1/es unknown
-
2024
- 2024-06-14 KR KR1020240077657A patent/KR20240099117A/ko active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089420A1 (en) * | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
| KR20200078312A (ko) * | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022209248A1 (en) | 2022-10-20 |
| CL2023002504A1 (es) | 2024-01-26 |
| MX2023010926A (es) | 2023-09-27 |
| PE20250672A1 (es) | 2025-03-04 |
| IL304365B1 (en) | 2024-12-01 |
| CA3205058C (en) | 2024-04-09 |
| US20240009317A1 (en) | 2024-01-11 |
| BR112023018530A2 (pt) | 2023-10-10 |
| EP4316528A1 (en) | 2024-02-07 |
| AR125263A1 (es) | 2023-06-28 |
| ZA202307219B (en) | 2024-10-30 |
| KR20240099117A (ko) | 2024-06-28 |
| US12599675B2 (en) | 2026-04-14 |
| KR20220136285A (ko) | 2022-10-07 |
| KR102680146B1 (ko) | 2024-07-04 |
| AU2022209248B2 (en) | 2023-06-29 |
| CN116916969A (zh) | 2023-10-20 |
| JP2024512418A (ja) | 2024-03-19 |
| CA3205058A1 (en) | 2022-10-26 |
| WO2022211537A1 (ko) | 2022-10-06 |
| EP4316528A4 (en) | 2026-03-11 |
| IL304365A (en) | 2023-09-01 |
| TW202304521A (zh) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12599675B2 (en) | Conjugate of immune-stimulating il-2 analog and preparation method thereof | |
| KR102946368B1 (ko) | 신규한 면역 활성 인터루킨 2 아날로그 | |
| EP3896085A1 (en) | Anti-human interleukin 5(il-5) monoclonal antibody and use thereof | |
| CN111944036A (zh) | 一种增殖免疫细胞的突变体蛋白 | |
| KR20220092442A (ko) | 신규한 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도 | |
| JP2023538236A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物 | |
| HK40100172A (en) | Novel immunoactive interleukin 2 analog conjugate and method for preparing same | |
| TWI922649B (zh) | 免疫刺激il-2類似物的新穎接合物及其製備方法 | |
| EP4678180A1 (en) | Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof | |
| EP4678181A1 (en) | Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer | |
| EA049515B1 (ru) | Новый конъюгат иммуностимулирующего аналога интерлейкина-2 и способ его получения | |
| HK40131569A (en) | Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof | |
| KR20260065576A (ko) | 암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 ctla-4 길항제의 병용 요법 | |
| CA3282636A1 (en) | Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof | |
| HK40130618A (en) | Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer | |
| KR20220041766A (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도 | |
| CA3282626A1 (en) | Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer | |
| TWI922560B (zh) | 新穎之三重升糖素/ｇｌｐ-１/ｇｉｐ受體促效劑及其用途 | |
| KR20230149258A (ko) | 장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법 | |
| KR20240102886A (ko) | 면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제 |